MONTE ROSA THERAPEUTICS INC (GLUE) Stock Price, Quote, News and Overview
NASDAQ:GLUE - Nasdaq - US61225M1027 - Common Stock - Currency: USD
GLUE Quote, Performance and Key Statistics
5.22
-0.11 (-2.06%)
The current stock price of GLUE is 5.22 USD. In the past month the price decreased by -4.92%. In the past year, price decreased by -2.06%.
GLUE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.82 | 319.07B | ||
| AMGN | AMGEN INC | 14.12 | 150.46B | ||
| GILD | GILEAD SCIENCES INC | 13.71 | 132.33B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698.17 | 126.60B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.14 | 65.57B | ||
| ARGX | ARGENX SE - ADR | 322.85 | 36.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.56B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.98B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.60B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 27.06B | ||
| NTRA | NATERA INC | N/A | 20.88B | ||
| BIIB | BIOGEN INC | 7.26 | 17.49B |
Related stock screener links
About GLUE
Company Profile
Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 133 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Company Info
MONTE ROSA THERAPEUTICS INC
321 Harrison Avenue, Suite 900
Boston MASSACHUSETTS US
CEO: Markus Warmuth
Employees: 129
Company Website: https://www.monterosatx.com/
Investor Relations: https://ir.monterosatx.com/
Phone: 16179492643
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
What is the stock price of MONTE ROSA THERAPEUTICS INC today?
The current stock price of GLUE is 5.22 USD. The price decreased by -2.06% in the last trading session.
What is the ticker symbol for MONTE ROSA THERAPEUTICS INC stock?
The exchange symbol of MONTE ROSA THERAPEUTICS INC is GLUE and it is listed on the Nasdaq exchange.
On which exchange is GLUE stock listed?
GLUE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MONTE ROSA THERAPEUTICS INC stock?
15 analysts have analysed GLUE and the average price target is 17.05 USD. This implies a price increase of 226.6% is expected in the next year compared to the current price of 5.22. Check the MONTE ROSA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MONTE ROSA THERAPEUTICS INC worth?
MONTE ROSA THERAPEUTICS INC (GLUE) has a market capitalization of 321.08M USD. This makes GLUE a Small Cap stock.
How many employees does MONTE ROSA THERAPEUTICS INC have?
MONTE ROSA THERAPEUTICS INC (GLUE) currently has 129 employees.
What are the support and resistance levels for MONTE ROSA THERAPEUTICS INC (GLUE) stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a support level at 4 and a resistance level at 5.34. Check the full technical report for a detailed analysis of GLUE support and resistance levels.
Is MONTE ROSA THERAPEUTICS INC (GLUE) expected to grow?
The Revenue of MONTE ROSA THERAPEUTICS INC (GLUE) is expected to grow by 158.24% in the next year. Check the estimates tab for more information on the GLUE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MONTE ROSA THERAPEUTICS INC (GLUE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GLUE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GLUE, evaluating the profitability, health, valuation and growth aspects
- MONTE ROSA THERAPEUTICS INC (GLUE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MONTE ROSA THERAPEUTICS INC (GLUE) Sales and EPS estimates to see what analysts future expectations are.
- MONTE ROSA THERAPEUTICS INC (GLUE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MONTE ROSA THERAPEUTICS INC (GLUE) Insider and Institutional Ownership to learn about the owners and their transactions.
- MONTE ROSA THERAPEUTICS INC (GLUE) Stock Chart to make your own analysis
- MONTE ROSA THERAPEUTICS INC (GLUE) Latest news and press-releases to stay up to date.
Does MONTE ROSA THERAPEUTICS INC (GLUE) stock pay dividends?
GLUE does not pay a dividend.
When does MONTE ROSA THERAPEUTICS INC (GLUE) report earnings?
MONTE ROSA THERAPEUTICS INC (GLUE) will report earnings on 2025-05-08, before the market open.
What is the Price/Earnings (PE) ratio of MONTE ROSA THERAPEUTICS INC (GLUE)?
MONTE ROSA THERAPEUTICS INC (GLUE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).
What is the Short Interest ratio of MONTE ROSA THERAPEUTICS INC (GLUE) stock?
The outstanding short interest for MONTE ROSA THERAPEUTICS INC (GLUE) is 11.56% of its float. Check the ownership tab for more information on the GLUE short interest.
GLUE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GLUE. When comparing the yearly performance of all stocks, GLUE turns out to be only a medium performer in the overall market: it outperformed 46.52% of all stocks.
GLUE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GLUE. While GLUE seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLUE Financial Highlights
Over the last trailing twelve months GLUE reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 61.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.57% | ||
| ROE | -32.61% | ||
| Debt/Equity | 0 |
GLUE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to GLUE. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -49.6% and a revenue growth 158.24% for GLUE